Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

被引：14

作者：

Chanthavanich, Pornthep ^{[1
]}

Limkittikul, Kriengsak ^{[1
]}

Sirivichayakul, Chukiat ^{[1
]}

Chokejindachai, Watcharee ^{[1
]}

Hattasingh, Weerawan ^{[1
]}

Pengsaa, Krisana ^{[1
]}

Surangsrirat, Surachai ^{[2
]}

Srisuwannaporn, Termsang ^{[2
]}

Kaewma, Benjawan ^{[2
]}

Yoksan, Sutee ^{[3
]}

Jun, Gao ^{[4
]}

Zhumu, Bai ^{[4
]}

机构：

[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, 420-6 Rajvithi Rd, Bangkok 10400, Thailand

[2] Nopparat Rajathanee Hosp, Minist Publ Hlth, Bangkok, Thailand

[3] Mahidol Univ, Inst Mol Biosci, Ctr Vaccine Dev, Japanese Encephalitis Dengue Virol Lab, Bangkok, Thailand

[4] Liaoning Cheng Da Biotechnol Co Ltd, Shenyang, Liaoning, Peoples R China

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期

关键词：

children; chromatographical purify; immunogenicity; Inactivated Vero cell-derived JE vaccine; pediatrics; safety; vaccinology; TRAVELERS;

D O I：

10.1080/21645515.2017.1414763

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.

引用

页码：900 / 905

页数：6

共 50 条

[1] Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
Hattasingh, Weerawan
Chanthavanich, Pornthep
Sirivichayakul, Chukiat
Arunsodsai, Watcharee
Surangsrirat, Surachai
Srisuwannaporn, Termsang
Kaewma, Benjawan
Yoksan, Sutee
Limkittikul, Kriengsak
Yang, Junwei
Mao, Yu
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
[2] Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults
Takeshita, Nozomi
Lim, Chang-Kweng
Mizuno, Yasutaka
Shimbo, Takuro
Kotaki, Akira
Ujiie, Mugen
Hayakawa, Kayoko
Kato, Yasuyuki
Kanagawa, Shuzo
Kaku, Mitsuo
Takasaki, Tomohiko
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2014, 20 (3-4) : 238 - 242
[3] Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®
Schuller, Elisabeth
Klingler, Anton
Dubischar-Kastner, Katrin
Dewasthaly, Shailesh
Mueller, Zsuzsanna
VACCINE, 2011, 29 (47) : 8669 - 8676
[4] The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis
Erra, Elina O.
Kantele, Anu
EXPERT REVIEW OF VACCINES, 2015, 14 (09) : 1167 - 1179
[5] Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
Zhang, Yuntao
Chen, Haiping
Lv, Jun
Huang, Tao
Zhang, Ruizhi
Zhang, Dongjuan
Luo, Linyun
Wei, Sheng
Liu, Xiaoqin
Zhang, Shangxiao
Mu, Qiuyue
Huang, Rongdong
Huang, Jiao
Xiao, Yanhui
Yang, Yunkai
Han, Yuting
Gong, Hao
Guan, Qinghu
Xie, Fangqin
Wang, Hui
Li, Liming
Yang, Xiaoming
VACCINES, 2022, 10 (07)
[6] Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region
Dubischar, Katrin L.
Kadlecek, Vera
Sablan, Benjamin
Borja-Tabora, Charissa Fay
Gatchalian, Salvacion
Eder-Lingelbach, Susanne
Kiermayr, Sigrid
Spruth, Martin
Westritschnig, Kerstin
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (09) : 898 - 904
[7] Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients
Assawawiroonhakarn, Surapat
Apiwattanakul, Nopporn
Pakakasama, Samart
Hongeng, Suradej
Anurathapan, Usanarat
Yoksan, Sutee
Klinmalai, Chompunuch
Sae-Chew, Pattarana
Techasaensiri, Chonnamet
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (03) : 264 - 268
[8] Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine
Yun, Ki Wook
Lee, Hoan Jong
Park, Ji Young
Cho, Hye-Kyung
Kim, Yae-Jean
Kim, Kyung-Hyo
Kim, Nam Hee
Hong, Young Jin
Kim, Dong Ho
Kim, Hwang Min
Cha, Sung-Ho
VACCINE, 2018, 36 (11) : 1398 - 1404
[9] Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia
Islam, Nazmul
Lau, Colleen
Leeb, Alan
Mills, Deborah
Furuya-Kanamori, Luis
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
[10] Immunogenicity and safety of the third booster dose of the inactivated Japanese encephalitis vaccine in Korean children: A prospective multicenter study
Kwak, Byung Ok
Kwon, Young Se
Hong, Young Jin
Shin, Seon Hee
Eun, Byung Wook
Ahn, Young Min
Kim, Hwang Min
Kim, Nam Hee
Kim, Dong Hyun
VACCINE, 2021, 39 (14) : 1929 - 1932

← 1 2 3 4 5 →